Early clinical diagnosis of an under-recognized form of amyloidosis that causes rapidly progressing polyneuropathy is crucial to improving patient outcomes. Worldwide, the most common mutation ...

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.